CASTOR1 functional inactivation drives KRAS-mutant NSCLC and therapy resistance by a noncanonical mechanism of tumor suppression
Menée à l'aide de lignées cellulaires, d'organoïdes et d'un modèle murin transgénique de cancer du poumon non à petites cellules lié à une mutation KRAS, cette étude met en évidence un mécanisme non canonique par lequel l'inactivation de CASTOR1, une protéine captant l'arginine cytosolique et régulant la voie de signalisation mTORC1, favorise le développement tumoral et la résistance aux inhibiteurs de KRAS, laquelle peut être levée par le ciblage de mTORC1 ou la double inhibition de la kinase PI3K et de mTOR
CASTOR1, a cytosolic arginine sensor and regulator of mTORC1 signaling, is identified here as a tumor suppressor in KRAS-driven non–small cell lung cancer (NSCLC). In a KRASG12D mouse model, CASTOR1 deletion enhances tumor initiation and progression, accompanied by increased proliferation. Although CASTOR1 is rarely mutated or deleted in human cancers, its expression progressively declines during tumor progression and is associated with increased AKT activation and CASTOR1 phosphorylation, consistent with functional inactivation. Loss of CASTOR1 results in constitutive mTORC1 hyperactivation, impaired arginine-dependent regulation of mTORC1 signaling, elevated p-4EBP1 and p-S6 levels, increased AKT and ERK activation, genomic instability, and resistance to KRASG12D inhibitors. Tumors and tumor-derived organoids deficient in CASTOR1 are resistant to KRAS inhibition, but this resistance can be overcome by cotargeting mTORC1 or dual PI3K/mTOR inhibition. These findings identify CASTOR1 as a critical link between nutrient sensing and oncogenic signaling and reveal its functional inactivation as an important mechanism contributing to KRAS-driven NSCLC progression and therapeutic resistance. The results further support rational combination therapies to overcome KRAS inhibitor resistance in CASTOR1-low NSCLC.
Science Advances , article en libre accès, 2026